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ABSTRACT 
Objective: To an assessment of potential drug-drug interactions in hypertensive patients in a tertiary care hospital. 
Methods: A prospective, observational study was conducted at a tertiary care hospital, Erode for a period of 8 mo. A sample of 480 patients was 
assessed for PDDIs using drug checker in Micromedex®
Results: A total of 430 patients were analyzed and it was found to be 396 (82.50%) hypertensive patients had PDDIs, and a sum total of 1160 PDDIs 
were observed. Potential drug-drug interactions (PDDIs) higher in female hypertensive patients [255 (64.39%)] compared to males. Incidences of 
PDDIs were found to be higher in the age group of 60-70 y were [177 (44.69%)] and incidences of interactions based on the duration of (4-6 d) 
hospital stays were 272 (68.68%). Moreover, 49.24% of patients were found to be prescribed with more than 7 drugs, with higher incidences of 
PDDIs. Some of the most common drug interacting pair was between aspirin and clopidogrel combination observed in 325 PDDIs in the major, with 
pharmacodynamics in nature. 
-2.7. 
Conclusion: Clinical pharmacist ought to have the role of regular monitoring of drug therapy in identifying and preventing the medications that have 
the potential to cause drug-drug interactions, thereby minimizing the undesirable outcomes in drug medical care and improving the quality of care.  
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Hypertension, also known as high or raised blood pressure, is a 
global public health issue. It contributes to the burden of heart 
disease, stroke and kidney failure, and premature mortality and 
disability. It disproportionately affects populations in low and 
middle-income countries where health systems are weak [1]. 
Hypertension rarely causes symptoms in the early stages and many 
people go undiagnosed. Those who are diagnosed may not have 
access to treatment and may not be able to successfully control their 
illness over the long-term [1-3]. 
The globally cardiovascular disease (CVD) accounts for approximately 
17 million deaths a year, nearly one-third of the total [4]. Of these, 
complications of hypertension account for 9.4 million deaths 
worldwide every year [5]. Hypertension is responsible for at least 45% 
of deaths due to heart disease (total ischemic heart disease mortality), 
and 51% of deaths due to stroke (total stroke mortality) [4]. In 2008, 
worldwide, approximately 40% of adults aged 25 and above had been 
diagnosed with hypertension; the number of people with the condition 
rose from 600 million in 1980 to1 billion in 2008 [6]. 
The prevalence of hypertension is highest in the African Region at 46% 
of adults aged 25 and above, while the lowest prevalence at 35% is 
found in the Americas. Overall, high-income countries have a lower 
prevalence of hypertension-35%-than other groups at 40% [7]. 
Drug prescription in HT is complex and many factors such as 
polypharmacy, comorbid conditions, pharmacokinetic and 
pharmacodynamic variability, and noncompliance make this group a 
high risk as far as drug safety is concerned [8-10]. To inform health 
care providers and to provide pragmatic clinical suggestions and 
recommendations, international, regional, and national 
hypertension guidelines have been developed by expert groups 
globally. Most major hypertension treatment guidelines currently 
suggest that clinicians should strive to treat adults to a blood 
pressure target of ≤140/90 mm Hg [3, 11]. 
MATERIALS AND METHODS 
The Research work was conducted in a tertiary care hospital, the 
work was reviewed and approved by the Institute Ethics Committee 
(Human Studies), ethics number is PP/2018/05 and hospital 
approved number is EMC/M PHARM/0140T18. Erode for a period of 
8 mo in the hospitalized hypertensive patients. 480 hypertensive 
cases were taken in for the study. Inclusion criteria patients of both 
genders, aged more than 18 y, prescriptions with or 2 more drugs 
prescribed throughout the hospitalization had been only decided on 
for the study. Exclusion criteria were outpatients, Prescription with 
much less than 2 drugs prescribed as well as patients less than 18 y 
old, and outpatients. The consent form was obtained from hospital 
authority and hospitalized patients. The data were collected from 
case sheets of hospitalized patients and direct patient interview 
from hypertensive patients. The demographic details consist of age, 
gender, the reason for admission, past medical records, medication 
records, co-morbidities and any records of hypersensitive reactions. 
All the collected data have been documented in the certainly 
designed data collection form designed as per the need of the study. 
The patient drug therapy was reviewed each day and assessed for 
drug interactions checker by way of the use of Micromedex®-2.7 
software. The diagnosed potential drug-drug interactions had been 
categorized into 3 groups based on severity, namely, minor, 
moderate, major and types respectively. 
RESULTS 
A total of 430 patients were analyzed and it was found to be 396 
(82.50%) hypertensive patients had PDDIs, and a sum total of 1160 
PDDIs were observed. Potential drug-drug interactions (PDDIs) 
higher in female hypertensive patients [255 (64.39%)] compared to 
males. Incidences of PDDIs were found to be higher in the age group 
of 60-70 y were [177 (44.69%)] and incidences of interactions based 
on the duration of (4-6 d) hospital stays were 272 (68.68%). 
Moreover, 49.24% of patients were found to be prescribed with 
more than 7 drugs, with higher incidences of PDDIs. 
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Table 1: Demographic profile of hypertensive patients 
S. No. Parameters Total number of patients (n=396) Percentage (%) 





























































Table 2: Distribution of co-morbidities diseases in hypertensive patients 
Co-morbidities disease Total number of patients with PDDIs(n=396) Percentage (%)  
Hypertension  162 40.90% 
Hypertension+Diabetes 68 17.17% 
Hypertension+Cardiovascular disease 41 10.35% 
Hypertension+Asthma 36 9.09% 
Hypertension+kidney disease 12 3.03% 
Pre-eclampsia 18 4.54% 
Hypertension+Diabetes+cardiovascular disease 39 9.84% 
Hypertension+Diabetes+Asthma 8 2.02% 
pre-eclampsia+Diabetes 12 3.03% 
On average, each patient had one or two coded diagnosis in which hypertension was the most common condition 162 (40.90%), followed by 
Hypertension with Diabetes mellitus 68 (17.17%) in hypertensive patients (table 2). 
 
Table 3: Highest potential drug-drug interaction combinations in hypertensive patients 
PDDIs combination Types Severity Frequency (n=1160) Percentage (%) 
Aspirin+Clopidogrel PD Major 325 28.01 
Amlodipine+Simvastatin Unknown Major 172 14.82 
Digoxin+Bisoprolol PD Moderate 85 7.32 
Captopril+Metformin PD Moderate 38 3.27 
Hydrochlorothiazide+Captopril  PD Moderate 41 3.53 
Enalapril+Furosemide PD Moderate 67 5.77 
Losartan+Captopril PK Major 47 4.05 
Spironolactone+Potassium chloride  PK Major 38 3.27 
Atenolol+Metformin PK Moderate 66 5.68 
Aspirin+Enalapril PD Moderate 39 3.36 
Note: PD= Pharmacodynamics, PK= Pharmacokinetics 
 
 
Fig. 1: Types of potential drug-drug interactions 
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Table 4: Anticipated effect, M. O. A, clinical management for common potential drug-drug interactions in hypertensive patients 
PDDIs combination Mechanism of action Anticipated effects Remedy 
Aspirin+Clopidogrel Additive Effect 
 
Increased risk of bleeding. Monitor for blood counts if co-
administration is needed 
Amlodipine+Simvastatin Unknown Increased simvastatin exposure and 
increased risk of myopathy, including 
rhabdomyolysis. 
Dose adjustment required. Simvastatin 
should not exceed 20 mg/day 
Digoxin+Bisoprolol additive effects on AV 
node conduction 
Increased risk of bradycardia and 
possible digitalis glycoside toxicity. 
Monitor heart rate and PR interval 
Captopril+Metformin Unknown Increased risk of hypoglycemia. Monitor glucose level 
Hydrochlorothiazide+Captopril Vasodilation and 
relative intravascular 
volume depletion 
Reduction of blood pressure Decreasing or discontinuing the diuretic or 
increasing salt intake may minimize the risk 
of hypotensive effects. 
Enalapril+Furosemide Synergistic Effect  Result in postural hypotension Discontinue the diuretic 2 or 3 d prior to 
ACEI 
Losartan+Captopril Dual blockade of the 
renin-angiotensin-
aldosterone system 
Increased risk of adverse events (ie, 
hypotension, syncope, hyperkalemia, 
changes in renal function, acute renal 
failure). 






May result in hyperkalemia. Discontinue potassium supplementations 
when spironolactone therapy is initiated. 
Monitor serum potassium closely. 
Atenolol+Metformin Altered glucose 
metabolism and beta-
blockade 
May result in hypoglycemia or 
hyperglycemia 
Monitor for blood glucose level. 
Aspirin+Enalapril Antagonistic Effect Decreased effectiveness of enalapril Weigh benefit and risk. 
 
Table 5: Types of the prevalence of PDDIs 
S. No. Severity of PDDIs Frequency (n=1160) Percentage (%) 
1. Major 381 32.84% 
2. Moderate 496 42.75% 
3. Minor 283 24.39% 
 
Out of 396 hypertensive patients, there was 96 interacting pair was 
identified during the study. Among 1160 PDDIs, 392 (33.79%) were 
pharmacokinetic interactions, 626 (53.96%) were pharmacodynamic 
interactions, 69 (05.94%) showing both mechanisms and 73 (06.29%) 
were an unknown mechanism. Among 392 pharmacokinetic drug 
interactions, 51 (13.01%) were due to absorption, 79 (20.15%) were 
due to distribution, 198 (50.51%) were due to metabolism and 64 
(16.32%) were due to excretion. Among 626 (53.96%) 
pharmacodynamics interactions, 68 (10.86%) were synergistic, 185 
(29.55%) were antagonistic, 324 (51.75%) were additive and 49 
(7.82%) with both additive and antagonistic effects. 
DISCUSSION 
Drug interactions are a major area of challenge in recent times for the 
effective management of patient contamination. It is able to create a 
great health hazard to the patients when the risk-benefit ratio of 
combining interacting drugs is not as it should be envisioned. It has 
already been approximated that the impact of drug interactions can 
range from any minor morbidity to fatal effects. The study of drug-
drug, interactions and of genetic factors affecting pharmacokinetics 
and pharmacodynamics is expected to improve drug protection and 
could allow individualized drug therapy. 
In our study identified a total of 480 hypertensive patients were 
admitted to the hospital during the study period. Among these, 480 
hypertensive patients, 396 (82.50%) had found to be PDDIs, 1160 
PDDIs were found in 396 hypertensive patients (fig. 1). Out of which 
255 (64.39%) female patients found to be higher PDDIs, compared 
to males 141 (35.60%), which are similar to the study conducted by 
Puspitasari et al., [12] (table 1). Wherein it was also reported that 
the prevalence of hypertension is higher in female patients than in 
male patients [2]. Female patients are more prone to hypertension 
than male patients based on their etiology and pathophysiology. As 
an example, hypertension due to renal artery stenosis is more 
common in females than males. Other factors that cause 
hypertension in females are the use of oral contraceptives, pre-
eclampsia, and vasculitis (inflammation of blood vessels) [3]. 
Our studies revealed that majority of the patients were found to be 
age group of 60-70 y, 177 (44.69%) (table 1). A study conducted by 
Kameswaran R et al. (2018) [13], reported that incidences of PDDIs 
were found to be higher in the age group of 60-70 y in cardiac [159 
(44.16%)] patients. Another study conducted by Santi Purna Sari et 
al. (2018) [17] ACE inhibitor was more frequently used in females 
(59.15%), patients aged ≥6 0 y (38.03%), and those with no 
impairments of liver or kidney function (36.62%). Polypharmacy 
was identified in 67 prescriptions, and most cases received 5–6 
drugs (50.75%). Older people were at high risk of developing an 
ADR due to pDDIs for several reasons. They are likely to have higher 
comorbidities and thus take several prescriptions and over the 
counter drugs. 
The study revealed that 272 (68.68%) of cases reported that a number 
of hospital stay was between 4-6 d. (table 4) Kameswaran R et al. 
(2018) [13] conducted a study which showed that the majority of the 
cases, the number of hospital stay were between 4-6 d. The likelihood 
of getting the multiple drugs increases with the increased length of 
hospital stay which in turn will increase the likelihood of PDDIs. 
In our study shows that 195 (49.24%) hypertensive patients were 
prescribed with more than 7 drugs (table 5). The study conducted by 
Puspitasari et al. (2015) [12] which have shown 57.14% of cases 
have been reported as the prescribing greater than 4. Types and 
combinations of prescribed antihypertension and the most 
prescribed drug for single prescriptions was amlodipine at 
Sukmajaya Community Health Center. Amlodipine has been shown 
to be a well-tolerated antihypertensive drug, especially in elderly 
patients. Amlodipine tolerability has also been shown to be good or 
excellent in most patients. This is because amlodipine is slowly 
absorbed, and the side effects of vasodilation tend to be smaller than 
other CCB-group drugs. Amlodipine also has a low rate of 
metabolism in the liver and a longer half-life than other drugs, 
allowing effective blood pressure control with once-daily dosing [5]. 
The study revealed that the highest number of diseases and co-
morbid conditions were hypertension alone were 162 (40.90%), 
Kameswaran et al. 
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hypertension+diabetes were 68 (17.17%), and Hypertension+ 
Cardiovascular diseases were 41 (10.35%), the most co-morbidities 
disease in hypertensive patients, and also the most of the female 
patients had found to be hypertensive and shown PDDIs (table 6), a 
similar study conducted by Romday et al. (2016) [14] reported that 
Diabetes mellitus (9.36%, males; 8.96%, females), other 
cardiovascular diseases (14.05%, males; 13.43%, females), acid 
peptic disease (7.69%, males; 7.46%, females) and dyslipidemia 
(11.70%, males; 13.43%, females) are the most common co-
morbidities in hypertension patients. 
The study shows that the highest monotherapy drugs prescribed 
were amlodipine 175, followed by telmisartan 65 patients, and 
olmesartan 58 patients. Combination of 2 drugs therapy were 
aspirin+clopidogrel 325 patients, followed by amlodipine+ 
simvastatin 172 patients, and Digoxin+bisoprolol 85 patients, 
whereas in a combination of 3 drugs therapy were telmisartan+ 
hydrochlorothiazide+metoprolol 4 patients, followed by 
furosemide+amlodipine+atenolol 3 patients. 
The highest most common interacting pair in hypertensive patients 
had found to be between aspirin and clopidogrel; causing major 
pharmacodynamics interaction, with a frequency of 325 (28.01%), 
followed by amlodipine and simvastatin; causing major severity, 
with a frequency of 172 (14.82%) (table 10). The similar to the 
study conducted by Kameswaran R et al. (2018) [13] in which some 
of the most common drug interacting pair was aspirin and 
clopidogrel; causing major, pharmacodynamics interaction, with a 
frequency of 245. 
The prevalence among 1160 PDDIs was 42.75% moderate in 
severity, 32.84% major severity and 24.39% minor severity (table 
12). A similar study was performed by Puspitasari et al. (2015) 
[12]showed an overall 61.70% were in moderate severity, 29.79% 
were in major severity and 8.51% were in minor severity among the 
study conducted in hypertensive patients. Another author conducted 
study (2018) [16] Among the DDIs, there were 324 (81.81%) 
moderate DDIs followed by 42 (10.61%) major DDIs and 30 (7.58%) 
minor DDIs. 
Out of 396 hypertensive patients, there was 96 interacting pair 
identified during the study. Among 1160 PDDIs, 392 (33.79%) were 
pharmacokinetic interactions, 626 (53.96%) were 
pharmacodynamic interactions, 69 (05.94%) showing both 
mechanisms and 73 (06.29%) were an unknown mechanism (table 
13). Among 392 pharmacokinetic drug interactions, 51 (13.01%) 
were due to absorption, 79 (20.15%) were due to distribution, 198 
(50.51%) were due to metabolism and 64 (16.32%) were due to 
excretion (table 14). Among 626 (53.96%) pharmacodynamic 
interactions, 68 (10.86%) were synergistic, 185 (29.55%) were 
antagonistic, 324 (51.75%) were additive and 49 (7.82%) with both 
additive and antagonistic effects (table 15). According to Nitin 
Kothari et al. (2014) [15], 
Limitation  
DDIs was affecting serum potassium level 
(32.24%). DDIs having unknown mechanism were 71 (7.73%) and 
pharmacokinetic DDIs were only 44 (4.79%). Out of 507 
pharmacodynamic DDIs, 366 were synergistic type while 141 were 
of an antagonistic type. Majority of synergistic pharmacodynamic 
DDIs, the software found, were between beta-blocker-calcium 
channel blocker (CCB) drug pair and beta blocker-angiotensin 
receptor blocker (ARB) drug pair. Beta-blocker and CCB both 
increase anti-hypertensive property of each other. 
The study was carried out in a hypothetical way of approach to find 
the prevalence of drug interactions. The active possibilities of DIs 
respect to the time of drug administration, the half-life of drugs, 
elimination time were not assessed. The study also could not assess 
the outcomes of DIs in the selected patients. 
CONCLUSION 
Clinical pharmacist ought to have the role of regular monitoring of 
drug therapy in identifying and preventing the medications that 
have the potential to cause drug-drug interactions thereby 
minimizing the undesirable outcomes in drug medical care and 
improving the quality of care. Use of electronic database systems as 
decision support tools, automated prescription alerts to doctors, 
conducting educational programs and watchful towards drug choice 
will decrease the negative outcomes of pDDIs. Therefore a daily 
review of the drug therapy by a clinical pharmacist during a 
multidisciplinary team might help to identify and prevent potential 
drug-drug interactions particularly in patients with chronic disease 
receiving multiple associated with their co-morbid conditions. These 
can successively help to optimize drug therapy, improve the quality 
of care and condense the undesirable outcomes within patient drug 
therapy. 
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